BioDelivery Sciences International (BDSI) versus Its Peers Critical Survey
BioDelivery Sciences International (NASDAQ: BDSI) is one of 113 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare BioDelivery Sciences International to related businesses based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, risk, valuation and earnings.
Volatility and Risk
BioDelivery Sciences International has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, BioDelivery Sciences International’s peers have a beta of 0.86, indicating that their average share price is 14% less volatile than the S&P 500.
Institutional & Insider Ownership
41.4% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 43.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.0% of BioDelivery Sciences International shares are held by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for BioDelivery Sciences International and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioDelivery Sciences International||0||1||5||0||2.83|
|BioDelivery Sciences International Competitors||949||3811||6046||164||2.49|
BioDelivery Sciences International presently has a consensus target price of $4.42, indicating a potential upside of 49.72%. As a group, “Pharmaceuticals” companies have a potential upside of 25.16%. Given BioDelivery Sciences International’s stronger consensus rating and higher probable upside, analysts plainly believe BioDelivery Sciences International is more favorable than its peers.
This table compares BioDelivery Sciences International and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioDelivery Sciences International||3.34%||14.64%||1.90%|
|BioDelivery Sciences International Competitors||-3,612.29%||-53.44%||-8.71%|
Earnings and Valuation
This table compares BioDelivery Sciences International and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|BioDelivery Sciences International||$44.33 million||-$31.81 million||-10.54|
|BioDelivery Sciences International Competitors||$7.79 billion||$2.46 billion||0.86|
BioDelivery Sciences International’s peers have higher revenue and earnings than BioDelivery Sciences International. BioDelivery Sciences International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
BioDelivery Sciences International beats its peers on 7 of the 12 factors compared.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.